CompletedPhase 1LSD
Effects of LSD on Neuroplasticity in Healthy Subjects
Sponsored by University of Fribourg
NCT ID
NCT05177419
Target Enrollment
45 participants
Start Date
2022-05-02
Est. Completion
2025-03-12
About This Study
Neuroplasticity is the brain's ability to reorganize itself and adapt in response to changing environmental conditions or pathological stimuli. LSD is a potent psychedelic drug which has been able to rapidly stimulate neuroplasticity in animal studies. Various authors have speculated that changes in neuroplasticity may contribute to LSD's long-term effects, but there is still little direct evidence that LSD or other psychedelics enhance neuroplasticity in humans. The goal of this study is to investigate the effects of LSD on several measures of neuroplasticity in healthy human subjects.
Conditions Studied
Interventions
- •Lysergic Acid Diethylamide
- •Lysergic Acid Diethylamide
Eligibility
Age:21 Years - 55 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: 1. Aged 21-55 2. Body mass index 18-29 3. Right-handed as assessed by the Edinburgh Handedness Inventory (score \> 60) 4. Fluent understanding of German 5. Willingness to adhere to study protocol 6. Willingness to refrain from taking illicit psychoactive substances for the duration of the study 7. Willingness to refrain from consuming alcohol for 24 hours before each study appointment. 8. Willingness to not operate a motor vehicle or other heavy machinery 48 hours after each substance administration. 9. Women of childbearing potential must be willing to use effective birth control during the study (e.g. birth control pill; condoms must be combined with a second reliable method). 10. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests will be repeated before each treatment day and must remain negative. 11. A friend or relative must be available to accompany the participant home following LSD appointments. Exclusion Criteria: 1. Severe chronic or acute medical condition 2. History of any seizure disorder, stroke, or cardiovascular illness 3. History of severe head trauma resulting in loss of consciousness 4. Personal or family history (first-degree relative) of psychotic disorders 5. Current or previous major neurological or psychiatric disorder within the last 3 years (e.g. major depression, anorexia, substance use disorder), 6. History of medically relevant suicide attempts 7. Current use of psychoactive medications 8. Lifetime use of hallucinogens, dissociatives, or entheogens more than 10 times, or any time within the previous three months 9. Regular (daily or near-daily) use of cannabis, alcohol, nicotine, or illicit substances 10. Pregnant or nursing women 11. Presence of any implanted, metal or electronic devices (e.g. pacemaker) 12. Recent or current participation in another clinical trial
Study Locations (1)
University of Fribourg
Fribourg, Canton of Fribourg, Switzerland